Search

Your search keyword '"Bourgeois, Christelle"' showing total 15 results
Start Over Author "Bourgeois, Christelle" Search Limiters Available in Library Collection
15 results on '"Bourgeois, Christelle"'

1. Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".

Author

Suez, Daniel, Stein, Mark, Gupta, Sudhir, Hussain, Iftikhar, Melamed, Isaac, Paris, Kenneth, Darter, Amy, Bourgeois, Christelle, Fritsch, Sandor, Leibl, Heinz, McCoy, Barbara, Gelmont, David, and Yel, Leman

Subjects
Humans, Immunologic Deficiency Syndromes, Immunoglobulin G, Injections, Subcutaneous, Reference Standards, Clinical Trials, Phase III as Topic, Drug-Related Side Effects and Adverse Reactions, Data Analysis, Good Health and Well Being, Immunology
Published
2017

2. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

Author

Suez, Daniel, Stein, Mark, Gupta, Sudhir, Hussain, Iftikhar, Melamed, Isaac, Paris, Kenneth, Darter, Amy, Bourgeois, Christelle, Fritsch, Sandor, Leibl, Heinz, McCoy, Barbara, Gelmont, David, and Yel, Leman

Subjects
Vaccine Related, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Adolescent, Adult, Aged, Aged, 80 and over, Bacterial Infections, Child, Child, Preschool, Female, Humans, Immunoglobulins, Intravenous, Immunologic Deficiency Syndromes, Infusions, Subcutaneous, Male, Middle Aged, Quality of Life, Treatment Outcome, Young Adult, Primary immunodeficiency diseases, Immunoglobulin replacement therapy, Subcutaneous administration, 20% immunoglobulin, Pharmacokinetics, 20 % immunoglobulin, Immunology
Abstract

Patients with primary immunodeficiency disease (PIDD) typically require life-long intravenous (IV) or subcutaneous (SC) immunoglobulin (Ig) replacement therapy to prevent recurrent infections. The efficacy, safety, and pharmacokinetics of a highly concentrated (20 %) Ig preparation for SC administration (IGSC 20 %) were evaluated in a prospective trial in patients with PIDD. A total of 74 patients (aged 3-83 years) received 4327 IGSC 20 % infusions over a median of 380.5 days. The rate of validated serious bacterial infections was 0.012 event/patient-year (p 14.5 g/l. The median maximum infusion rate was 60 ml/h/site (range 4.4-180), resulting in a median infusion duration of 0.95 h. A volume ≥30 ml was infused per site in 74.8 % of IGSC 20 % infusions. Most (84.9 %) infusions were administered using ≤2 infusion sites; for 99.8 % of infusions, there was no need to interrupt/stop administration or reduce the infusion rate. No related serious adverse event (AE) occurred during IGSC 20 % treatment; related non-serious AEs occurred at a rate of 0.036 event/infusion. The incidence of related local AEs was 0.015 event/infusion and of related systemic AEs was 0.021 event/infusion; most were mild in severity, none severe. Increased infusion rates or volumes were not associated with higher AE rates. The investigated IGSC 20 % treatment was shown to be effective and safe, enabling higher infusion rates and volumes per site compared to conventional SC treatments, resulting in fewer infusion sites and shorter infusion durations.

Published
2016

4. Type I Interferon Response Dysregulates Host Iron Homeostasis and Enhances Candida glabrata Infection

Author

Riedelberger, Michael, primary, Penninger, Philipp, additional, Tscherner, Michael, additional, Seifert, Markus, additional, Jenull, Sabrina, additional, Brunnhofer, Carina, additional, Scheidl, Bernhard, additional, Tsymala, Irina, additional, Bourgeois, Christelle, additional, Petryshyn, Andriy, additional, Glaser, Walter, additional, Limbeck, Andreas, additional, Strobl, Birgit, additional, Weiss, Guenter, additional, and Kuchler, Karl, additional

Published
2020
Full Text
View/download PDF

9. Estradiol impairs the Th17 immune response againstCandida albicans

Author

Relloso, Miguel, primary, Aragoneses-Fenoll, Laura, additional, Lasarte, Sandra, additional, Bourgeois, Christelle, additional, Romera, Gema, additional, Kuchler, Karl, additional, Corbí, Angel L., additional, Muñoz-Fernández, M. Angeles, additional, Nombela, César, additional, Rodríguez-Fernández, José L., additional, and Diez-Orejas, Rosalia, additional

Published
2011
Full Text
View/download PDF

15. Estradiol impairs the Th17 immune response against Candida albicans

Author

Relloso, Miguel, Aragoneses‐Fenoll, Laura, Lasarte, Sandra, Bourgeois, Christelle, Romera, Gema, Kuchler, Karl, Corbí, Angel L., Muñoz‐Fernández, M. Angeles, Nombela, César, Rodríguez‐Fernández, José L., and Diez‐Orejas, Rosalia

Abstract

In vivo and ex vivo E2‐treated DCs have diminished ability to trigger the Th17 immune response against C. albicansantigens. Candida albicansis a commensal opportunistic pathogen that is also a member of gastrointestinal and reproductive tract microbiota. Exogenous factors, such as oral contraceptives, hormone replacement therapy, and estradiol, may affect susceptibility to Candidainfection, although the mechanisms involved in this process have not been elucidated. We used a systemic candidiasis model to investigate how estradiol confers susceptibility to infection. We report that estradiol increases mouse susceptibility to systemic candidiasis, as in vivo and ex vivo estradiol‐treated DCs were less efficient at up‐regulating antigen‐presenting machinery, pathogen killing, migration, IL‐23 production, and triggering of the Th17 immune response. Based on these results, we propose that estradiol impairs DC function, thus explaining the increased susceptibility to infection during estrus.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results